Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 2/20 | 0.40 |
| ▸ | AKT2 | P31751 | 1/20 | 0.40 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.39 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12072271 | 0.92 | PIK3CD (0.39) | ALOX5APPIK3CD | |
| SCHEMBL881851 | 0.84 | AKR1C3 (0.35) | ALOX5APPIK3CD | |
| SCHEMBL31158358 | 0.84 | DRD2 (0.40) | AKT1AKT2PIK3CD | |
| SCHEMBL23647450 | 0.84 | DRD2 (0.40) | AKT1AKT2PIK3CD | |
| SCHEMBL21848271 | 0.77 | DRD2 (0.39) | ALOX5AP | |
| SCHEMBL23647443 | 0.76 | NAPRT (0.39) | AKT2 | |
| SCHEMBL30702522 | 0.74 | CCR3 (0.50) | — | |
| SCHEMBL16441380 | 0.74 | LMNA (0.43) | ALOX5AP | |
| SCHEMBL1959786 | 0.73 | TRPA1 (0.41) | — | |
| SCHEMBL3567997 | 0.73 | AKT1 (0.38) | AKT1AKT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021074279-A1 | SPIRO-FUSED TRICYCLIC MAP4K1 INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 2021-04-22 | — | — | WO | disclosed |
| WO-2012082817-A1 | BIARYLAMIDE INHIBITORS OF LEUKOTRIENE PRODUCTION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-21 | — | — | WO | disclosed |
| WO-2012040139-A1 | OXADIAZOLE INHIBITORS OF LEUKOTRIENE PRODUCTION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-03-29 | — | — | WO | disclosed |